PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
+18.83%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.45%
AUM
$2.67B
AUM Growth
+$2.67B
(-5.5%)
Cap. Flow
-$524M
Cap. Flow
% of AUM
-19.65%
Top 10 Holdings %
Top 10 Hldgs %
54.89%
Holding
105
New
17
Increased
12
Reduced
35
Closed
21
Top Buys
| 1 |
Ascendis Pharma
ASND
|
$166M |
| 2 |
OMDA
Omada Health, Inc. Common Stock
OMDA
|
$44.4M |
| 3 |
Roivant Sciences
ROIV
|
$37.5M |
| 4 |
CAI
Caris Life Sciences, Inc. Common Stock
CAI
|
$29.3M |
| 5 |
Neurocrine Biosciences
NBIX
|
$19.5M |
Top Sells
| 1 |
Lyra Therapeutics
LYRA
|
$112M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$104M |
| 3 |
VRNA
Verona Pharma
VRNA
|
$99.9M |
| 4 |
Soleno Therapeutics
SLNO
|
$90.2M |
| 5 |
Amicus Therapeutics
FOLD
|
$80.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Viking Therapeutics
VKTX
$3.08B
| $10.1M | 0.37% |
380,700
-128,305
| -25% | -$3.4M |
|
52
Ultragenyx Pharmaceutical
RARE
$3.1B
| $9.82M | 0.36% |
+270,000
| New | +$9.82M |
|
53
Kymera Therapeutics
KYMR
$2.92B
| $9.17M | 0.34% |
+210,106
| New | +$9.17M |
|
54
Nautilus Biotechnolgy
NAUT
$84.7M
| $9.13M | 0.34% |
12,594,211
| – | – |
|
55
Penumbra
PEN
$10.5B
| $8.42M | 0.31% |
+32,797
| New | +$8.42M |
|
|
CBIO
56
Crescent Biopharma, Inc. Common Stock
CBIO
$190M
| $7.32M | 0.27% |
+453,686
| New | +$7.32M |
|
57
Aquestive Therapeutics
AQST
$466M
| $7.25M | 0.27% |
2,190,420
-1,536,788
| -41% | -$5.09M |
|
58
Janux Therapeutics
JANX
$1.37B
| $6.76M | 0.25% |
292,686
-677,726
| -70% | -$15.7M |
|
|
AVR
59
Anteris Technologies Global Corp. Common Stock
AVR
$148M
| $6.46M | 0.24% |
1,705,130
-434,870
| -20% | -$1.65M |
|
60
Xenon Pharmaceuticals
XENE
$3.03B
| $6.28M | 0.23% |
200,791
-124,533
| -38% | -$3.9M |
|
61
Viridian Therapeutics
VRDN
$1.56B
| $6.26M | 0.23% |
447,507
-212,155
| -32% | -$2.97M |
|
62
Corvus Pharmaceuticals
CRVS
$423M
| $5.75M | 0.21% |
+1,438,595
| New | +$5.75M |
|
|
SEPN
63
Septerna, Inc. Common Stock
SEPN
$552M
| $5.72M | 0.21% |
+541,450
| New | +$5.72M |
|
64
Globus Medical
GMED
$8.08B
| $5.22M | 0.19% |
+88,500
| New | +$5.22M |
|
65
enVVeno Medical
NVNO
$15.5M
| $5.13M | 0.19% |
+1,284,966
| New | +$5.13M |
|
|
BBOT
66
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$741M
| $4.23M | 0.16% |
398,000
| – | – |
|
|
IRD
67
Opus Genetics, Inc. Common Stock
IRD
$73.7M
| $4.07M | 0.15% |
4,325,000
| – | – |
|
|
CTNM
68
Contineum Therapeutics
CTNM
$316M
| $2.78M | 0.1% |
699,486
-741,763
| -51% | -$2.94M |
|
|
69
Lyra Therapeutics
LYRA
$12.2M
| $2.29M | 0.08% |
255,150
-12,502,412
| -98% | -$112M |
|
70
scPharmaceuticals
SCPH
$296M
| $1.91M | 0.07% |
500,000
| – | – |
|
71
Athira Pharma
ATHA
$15.2M
| $1.63M | 0.06% |
5,402,964
| – | – |
|
72
RAPT Therapeutics
RAPT
$193M
| $1.47M | 0.05% |
183,890
-4,235,057
| -96% | -$33.9M |
|
|
TRIB
73
Trinity Biotech
TRIB
$5.25M
| $1.16M | 0.04% |
+1,790,000
| New | +$1.16M |
|
74
Forte Biosciences
FBRX
$136M
| $882K | 0.03% |
+68,192
| New | +$882K |
|
75
Avalo Therapeutics
AVTX
$119M
| $697K | 0.03% |
139,667
-380,333
| -73% | -$1.9M |
|